The Apex Times
Above the Noise
Business Wire
BusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex TimesBusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex TimesBusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex TimesBusinessNetflix confirms production of ‘The Trauma Code: Heroes on Call’ Seasons 2 and 3The Apex TimesBusinessAEP Commits About $4 Billion to a Wyoming Fuel-Cell Project Tied to Google’s 20-Year Power PurchaseThe Apex TimesBusinessElon Musk Says He Lacks a Blueprint for Chipmaking, Suggesting Tesla-Backed Learning Could Be NextThe Apex TimesBusinessSpaceX’s growing “race to orbit” footprint pulls Tesla investors into the same narrative, Musk hintsThe Apex TimesBusinessMeta and three other bellwethers face a guidance test as investors look past earnings headlinesThe Apex TimesBusinessBond traders are indicating more caution toward Nvidia, a shift investors are watching closelyThe Apex TimesBusinessDow Jones futures rebound as investors eye major tech earnings, starting with MetaThe Apex TimesBusinessNVIDIA’s growth thesis comes into focus as investors refocus on profitable companies amid hotter inflation printsThe Apex TimesBusinessWall Street looks to earnings as AI worries pressure megacap techThe Apex TimesBusinessJim Cramer reiterated a $250 Palantir price target, but PLTR closed about 11% lower amid a broader AI selloffThe Apex TimesBusinessInvestors Question the AI Trade as Microsoft Points to Azure and CopilotThe Apex TimesBusinessElon Musk’s ex says she declined a reported $40 million NDA, then child support fell to about $5 million total, according to a new documentaryThe Apex Times
Back to front
Certara to integrate NVIDIA BioNeMo AI agents into drug development platform
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 7, 9:30 AM EDT

Certara to integrate NVIDIA BioNeMo AI agents into drug development platform

The drug-discovery software company said it will connect its biosimulation tools and regulatory know-how with NVIDIA’s BioNeMo Agent Toolkit, aiming to automate more of the analysis that supports dosing, trial simulation, ADMET screening and regulatory-ready evidence.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Certara, Inc. said it is partnering with NVIDIA to strengthen the AI capabilities of its drug development platform by integrating NVIDIA’s BioNeMo Agent Toolkit. Certara frames the move as a way to add “autonomous” life sciences AI agents into its workflow, while keeping scientists in control of decisions throughout the process.

According to Certara’s announcement as republished by StockTitan, the BioNeMo Agent Toolkit will be integrated into Certara’s “open integrated AI platform.” The goal is to let agents connect reasoning over models and clinical data with Certara’s existing resources, including biosimulation software, proprietary datasets, and regulatory expertise.

The companies said the agents are designed to generate specialized insights across multiple stages of the drug discovery and development lifecycle. That includes optimizing dosing, simulating clinical trials, evaluating ADMET properties, and supporting preparation of regulatory-ready evidence, with researchers retaining the decision-making role rather than fully delegating scientific judgment to the software.

ADMET is a common abbreviation in pharmaceutical research for absorption, distribution, metabolism, excretion, and toxicity. Certara did not provide additional technical detail in the republished announcement about how the agents calculate or validate these properties, beyond describing them as part of the agents’ targeted outputs.

Certara’s pitch centers on shifting AI from providing isolated predictions to orchestrating more end-to-end analysis tasks. By using agent-style automation, the company is aiming to reduce manual effort for scientists who assemble evidence across dosing strategies, trial simulation artifacts, and downstream regulatory documentation.

NVIDIA’s BioNeMo Agent Toolkit is positioned in the announcement as the mechanism that enables these agents to operate. Certara said the integration extends its broader investment in AI for biosimulation and life sciences analytics, but it did not describe timelines, customer rollouts, or which specific modules of its platform will be enabled first.

As with many partnership announcements in enterprise software, the company did not disclose performance benchmarks, accuracy targets, or how outputs will be audited for compliance. The republished announcement also does not specify whether the agents will be deployed on-premises, through a particular cloud environment, or how any validation studies would be structured with pharmaceutical clients.

For now, the practical question is how quickly Certara can convert an integration into sustained usage by biotech and pharmaceutical teams. The company’s next updates may clarify deployment details, integrations with particular datasets or regulatory workflows, and evidence of measurable cycle-time reduction in drug development processes.

Why It Matters

  • Drug development teams are increasingly looking for AI tools that go beyond predictions and help coordinate multi-step evidence creation across dosing, trials, and regulatory support.
  • Agent-style automation could reduce time spent assembling analyses, but the impact will depend on how reliably the agents produce validated, regulator-friendly outputs.
  • For NVIDIA, partnerships like this broaden BioNeMo’s application footprint into enterprise life sciences workflows.
  • For Certara, the integration is a step toward differentiating its biosimulation platform with more agent-driven functionality, which may influence buyer evaluation of AI-enabled drug discovery suites.

Sources

Key Facts

  • Certara announced a collaboration with NVIDIA to integrate the NVIDIA BioNeMo Agent Toolkit into Certara’s AI platform.
  • The integration is described as adding autonomous life sciences AI agents to Certara’s open integrated AI platform.
  • Certara said the agents will be able to reason over models and clinical data to generate specialized insights.
  • The stated use cases include optimizing dosing, simulating trials, evaluating ADMET, and preparing regulatory-ready evidence.
  • The announcement emphasizes keeping scientists in the decision-making loop rather than fully automating scientific judgment.

Technology Related

Oct 18, 6:12 PM EDT
The Apex Times

Wall Street looks to earnings as AI worries pressure megacap tech

Equity index futures rose after sharp selling tied to fresh concerns about the durability of the artificial-intelligence trade, with traders pointing to upcoming results from Meta and other major technology names.

Wall Street looks to earnings as AI worries pressure megacap tech
The Apex Times